

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

	(Unaudited; Dollars in Millions)				
	SECOND QUARTER				
	2008	2007	Total	Percent Change	
Operations				Currency	
Sales to customers by segment of business					
Consumer					
U.S.	\$ 1,694	1,562	8.5 %	8.5	-
International	2,342	2,002	17.0	5.6	11.4
	4,036	3,564	13.2	6.8	6.4
Pharmaceutical					
U.S.	3,793	3,860	(1.7)	(1.7)	-
International	2,547	2,289	11.3	(0.6)	11.9
	6,340	6,149	3.1	(1.3)	4.4
Med Devices & Diagnostics					
U.S.	2,723	2,619	4.0	4.0	-
International	3,351	2,799	19.7	7.3	12.4
	6,074	5,418	12.1	5.7	6.4
U.S.	8,210	8,041	2.1	2.1	-
International	8,240	7,090	16.2	4.3	11.9
Worldwide	\$16,450	15,131	8.7 %	3.1	5.6

	SIX MONTHS				
	2008	2007	Total	Percent Change	
				Operations	Currency
	3,513	3,191	10.1 %	10.1	-
	4,587	3,869	18.6	7.0	11.6
	8,100	7,060	14.7	8.3	6.4
	7,863	7,894	(0.4)	(0.4)	-
	4,906	4,476	9.6	(1.8)	11.4
	12,769	12,370	3.2	(0.9)	4.1
	5,311	5,203	2.1	2.1	-
	6,464	5,535	16.8	5.0	11.8
	11,775	10,738	9.7	3.6	6.1
	16,687	16,288	2.4	2.4	-
	15,957	13,880	15.0	3.4	11.6
	\$ 32,644	30,168	8.2 %	2.8	5.4

Johnson & Johnson and Subsidiaries
Supplementary Sales Data

	SECOND QUARTER						SIX MONTHS						
			Percent Change						Percent Change				
	2008	2007	Total	Operations	Currency	2008	2007	Total	Operations	Currency			
Sales to customers by geographic area													
U.S.	\$ 8,210	8,041	2.1 %	2.1	-	\$ 16,687	16,288	2.4 %	2.4	-			
Europe	4,547	3,907	16.4	2.4	14.0	8,855	7,720	14.7	1.6	13.1			
Western Hemisphere excluding U.S.	1,280	1,131	13.2	3.3	9.9	2,525	2,177	16.0	4.7	11.3			
Asia-Pacific, Africa	2,413	2,052	17.6	8.5	9.1	4,577	3,983	14.9	5.9	9.0			
International	8,240	7,090	16.2	4.3	11.9	15,957	13,880	15.0	3.4	11.6			
Worldwide	\$ 16,450	15,131	8.7 %	3.1	5.6	\$ 32,644	30,168	8.2 %	2.8	5.4			

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SECOND QUARTER

	2008		2007		Percent Increase (Decrease)	
	Amount	Percent to Sales	Amount	Percent to Sales		
Sales to customers	\$ 16,450	100.0	\$ 15,131	100.0	8.7	
Cost of products sold	4,751	28.9	4,358	28.8	9.0	
Selling, marketing and administrative expenses	5,507	33.5	5,029	33.3	9.5	
Research expense	1,896	11.5	1,866	12.3	1.6	
In-process research & development	40	0.2	-	-		
Interest (income)expense, net	16	0.1	(36)	(0.2)		
Other (income)expense, net	(135)	(0.8)	(117)	(0.8)		
Earnings before provision for taxes on income	4,375	26.6	4,031	26.6	8.5	
Provision for taxes on income	1,048	6.4	950	6.2	10.3	
Net earnings	\$ 3,327	20.2	\$ 3,081	20.4	8.0	
Net earnings per share (Diluted)	\$ 1.17		\$ 1.05		11.4	
Average shares outstanding (Diluted)	2,844.8		2,922.5			
Effective tax rate	24.0 %		23.6 %			
Adjusted earnings before provision for taxes and net earnings						
Earnings before provision for taxes on income	\$ 4,415	(1)	26.8	\$ 4,031	26.6	9.5
Net earnings	\$ 3,367	(1)	20.5	\$ 3,081	20.4	9.3
Net earnings per share (Diluted)	\$ 1.18	(1)		\$ 1.05		12.4
Effective tax rate	23.7%			23.6%		

(1) The difference between as reported earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

Johnson & Johnson and Subsidiaries
Condensed Consolidated Statement of Earnings

(Unaudited; in Millions Except Per Share Figures)

SIX MONTHS

	2008		2007		Percent Increase (Decrease)
	Amount	Percent to Sales	Amount	Percent to Sales	
Sales to customers	\$ 32,644	100.0	\$ 30,168	100.0	8.2
Cost of products sold	9,365	28.7	8,743	29.0	7.1
Selling, marketing and administrative expenses	10,630	32.6	9,831	32.5	8.1
Research expense	3,608	11.1	3,518	11.7	2.6
In-process research & development	40	0.1	807	2.7	
Interest (income)expense, net	32	0.1	(69)	(0.2)	
Other (income)expense, net	(153)	(0.5)	(345)	(1.1)	
Earnings before provision for taxes on income	9,122	27.9	7,683	25.4	18.7
Provision for taxes on income	2,197	6.7	2,029	6.7	8.3
Net earnings	\$ 6,925	21.2	\$ 5,654	18.7	22.5
Net earnings per share (Diluted)	\$ 2.43		\$ 1.93		25.9
Average shares outstanding (Diluted)	2,856.1		2,924.9		
Effective tax rate	24.1 %		26.4 %		

Adjusted earnings before provision for taxes and net earnings							
Earnings before provision for taxes on income	\$	9,162	(1)	28.1	\$ 8,490 (2)	28.1	7.9
Net earnings	\$	6,965	(1)	21.3	\$ 6,461 (2)	21.4	7.8
Net earnings per share (Diluted)	\$	2.44	(1)		\$ 2.21 (2)		10.4
Effective tax rate		24.0%			23.9%		

(1) The difference between as reported earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$40 million with no tax benefit and \$0.01 per share, respectively.

(2) The difference between as reported earnings before provision for taxes on income and net earnings and net earnings per share (diluted) is IPR&D of \$807 million with no tax benefit and \$0.28 per share, respectively.



REPORTED SALES vs. PRIOR PERIOD
SMM

PHARMACEUTICAL SEGMENT (2) (3)

ACIPHEX/PARIET

	SECOND QUARTER					SIX MONTHS				
	2008	2007	% Change (1)			2008	2007	% Change (1)		
		Reported	Operational	Currency			Reported	Operational	Currency	
US	153	161	-5.0%	-5.0%	-	269	320	-15.9%	-15.9%	-
Intl	172	175	-1.7%	-11.8%	10.1%	333	352	-5.4%	-15.7%	10.3%
WW	325	336	-3.3%	-8.6%	5.3%	602	672	-10.4%	-15.8%	5.4%

CONCERTA

US	208	199	4.5%	4.5%	-	432	399	8.3%	8.3%	-
Intl	71	57	24.6%	12.6%	12.0%	137	109	25.7%	13.7%	12.0%
WW	279	256	9.0%	6.3%	2.7%	569	508	12.0%	9.4%	2.6%

DURAGESIC/FENTANYL TRANSDERMAL

US	70	96	-27.1%	-27.1%	-	145	212	-31.6%	-31.6%	-
Intl	202	192	5.2%	-6.6%	11.8%	360	379	-5.0%	-15.3%	10.3%
WW	272	288	-5.6%	-13.5%	7.9%	505	591	-14.6%	-21.2%	6.6%

LEVAQUIN/FLOXIN

US	330	344	-4.1%	-4.1%	-	804	803	0.1%	0.1%	-
Intl	21	20	5.0%	-0.2%	5.2%	43	40	7.5%	2.0%	5.5%
WW	351	364	-3.6%	-3.9%	0.3%	847	843	0.5%	0.2%	0.3%

PROCRI/EXPRES

US	346	449	-22.9%	-22.9%	-	680	979	-30.5%	-30.5%	-
Intl	306	309	-1.0%	-12.7%	11.7%	601	596	0.8%	-11.1%	11.9%
WW	652	758	-14.0%	-18.8%	4.8%	1,281	1,575	-18.7%	-23.2%	4.5%

RAZADYNE/REMINYL

US	42	51	-17.6%	-17.6%	-	92	102	-9.8%	-9.8%	-
Intl	110	81	35.8%	19.7%	16.1%	209	158	32.3%	16.8%	15.5%
WW	152	132	15.2%	5.4%	9.8%	301	260	15.8%	6.4%	9.4%

REMICADE

US	684	625	9.4%	9.4%	-	1,360	1,225	11.0%	11.0%	-
US Exports (4)	200	244	-18.0%	-18.0%	-	520	375	38.7%	38.7%	-
Intl	2	-	100.0%	100.0%	-	4	-	100.0%	100.0%	-
WW	886	869	2.0%	2.0%	-	1,884	1,600	17.8%	17.8%	-

RISPERDAL

US	492	540	-8.9%	-8.9%	-	1,074	1,099	-2.3%	-2.3%	-
Intl	220	308	-28.6%	-36.6%	8.0%	447	616	-27.4%	-35.1%	7.7%
WW	712	848	-16.0%	-18.9%	2.9%	1,521	1,715	-11.3%	-14.1%	2.8%

RISPERDAL CONSTA

US	120	102	17.6%	17.6%	-	221	203	8.9%	8.9%	-
Intl	223	176	26.7%	12.2%	14.5%	431	336	28.3%	13.9%	14.4%
WW	343	278	23.4%	14.2%	9.2%	652	539	21.0%	12.0%	9.0%

TOPAMAX

US	548	472	16.1%	16.1%	-	1,068	973	9.8%	9.8%	-
Intl	129	106	21.7%	9.3%	12.4%	255	215	18.6%	6.7%	11.9%
WW	677	578	17.1%	14.8%	2.3%	1,323	1,188	11.4%	9.3%	2.1%

VELCADE

US	1	1	-	-	-	3	3	-	-	-
Intl	204	125	63.2%	47.0%	16.2%	386	236	63.6%	48.4%	15.2%
WW	205	126	62.7%	46.8%	15.9%	389	239	62.8%	47.8%	15.0%

OTHER

US	599	576	4.0%	4.0%	-	1,195	1,201	-0.5%	-0.5%	-
Intl	887	740	19.9%	5.0%	14.9%	1,700	1,439	18.1%	3.8%	14.3%
WW	1,486	1,316	12.9%	4.5%	8.4%	2,895	2,640	9.7%	1.9%	7.8%

TOTAL PHARMACEUTICAL

US	3,793	3,860	-1.7%	-1.7%	-	7,863	7,894	-0.4%	-0.4%	-
Intl	2,547	2,289	11.3%	-0.6%	11.9%	4,906	4,476	9.6%	-1.8%	11.4%
WW	6,340	6,149	3.1%	-1.3%	4.4%	12,769	12,370	3.2%	-0.9%	4.1%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) For external purposes, reported as U.S. sales



REPORTED SALES vs. PRIOR PERIOD

SMM

	SECOND QUARTER					SIX MONTHS				
	2008	2007	% Change			2008	2007	% Change		
			Reported	Operational (1)	Currency			Reported	Operational (1)	Currency
MEDICAL DEVICES AND DIAGNOSTICS (2) (3)										
<u>CORDIS (4)</u>										
US	348	397	-12.3%	-12.3%	-	705	821	-14.1%	-14.1%	-
Intl	504	455	10.8%	-1.1%	11.9%	982	959	2.4%	-8.3%	10.7%
WW	852	852	0.0%	-6.4%	6.4%	1,687	1,780	-5.2%	-11.0%	5.8%
<u>DEPUY</u>										
US	702	663	5.9%	5.9%	-	1,396	1,341	4.1%	4.1%	-
Intl	587	472	24.4%	12.2%	12.2%	1,146	951	20.5%	8.8%	11.7%
WW	1,289	1,135	13.6%	8.5%	5.1%	2,542	2,292	10.9%	6.1%	4.8%
<u>DIABETES CARE</u>										
US	338	310	9.0%	9.0%	-	641	602	6.5%	6.5%	-
Intl	336	286	17.5%	4.1%	13.4%	648	543	19.3%	5.9%	13.4%
WW	674	596	13.1%	6.7%	6.4%	1,289	1,145	12.6%	6.2%	6.4%
<u>ETHICON (5)</u>										
US	374	351	6.6%	6.6%	-	715	696	2.7%	2.7%	-
Intl	646	553	16.8%	5.1%	11.7%	1,250	1,082	15.5%	4.0%	11.5%
WW	1,020	904	12.8%	5.7%	7.1%	1,965	1,778	10.5%	3.5%	7.0%
<u>ETHICON ENDO-SURGERY</u>										
US	484	454	6.6%	6.6%	-	913	871	4.8%	4.8%	-
Intl	640	503	27.2%	13.4%	13.8%	1,214	977	24.3%	11.3%	13.0%
WW	1,124	957	17.5%	10.4%	7.1%	2,127	1,848	15.1%	8.3%	6.8%
<u>ORTHO-CLINICAL DIAGNOSTICS (5)</u>										
US	250	231	8.2%	8.2%	-	488	464	5.2%	5.2%	-
Intl	226	190	18.9%	6.3%	12.6%	431	365	18.1%	5.8%	12.3%
WW	476	421	13.1%	7.4%	5.7%	919	829	10.9%	5.5%	5.4%
<u>VISION CARE</u>										
US	227	213	6.6%	6.6%	-	453	408	11.0%	11.0%	-
Intl	412	340	21.2%	9.5%	11.7%	793	658	20.5%	9.3%	11.2%
WW	639	553	15.6%	8.4%	7.2%	1,246	1,066	16.9%	10.0%	6.9%
<u>TOTAL MEDICAL DEVICES AND DIAGNOSTICS</u>										
US	2,723	2,619	4.0%	4.0%	-	5,311	5,203	2.1%	2.1%	-
Intl	3,351	2,799	19.7%	7.3%	12.4%	6,464	5,535	16.8%	5.0%	11.8%
WW	6,074	5,418	12.1%	5.7%	6.4%	11,775	10,738	9.7%	3.6%	6.1%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)

(3) Prior year amounts have been reclassified to conform with current presentation

(4) Includes sales of Drug-Eluting Stents for Q2 2008 of \$167, \$227 and \$394 million Domestic, International and Worldwide respectively
 Includes sales of Drug-Eluting Stents for Q2 2007 of \$209, \$234 and \$443 million Domestic, International and Worldwide respectively
 Includes sales of Drug-Eluting Stents for June YTD 2008 of \$336, \$458 and \$794 million Domestic, International and Worldwide respectively
 Includes sales of Drug-Eluting Stents for June YTD 2007 of \$445, \$526 and \$971 million Domestic, International and Worldwide respectively

(5) Restated to include portion of sales previously reported in the "Other" category



REPORTED SALES vs. PRIOR PERIOD

SMM

CONSUMER SEGMENT (2)

SKIN CARE

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	379	338	12.1%	12.1%	-
Intl	460	419	9.8%	-1.1%	10.9%
WW	839	757	10.8%	4.7%	6.1%

BABY CARE

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	111	106	4.7%	4.7%	-
Intl	461	381	21.0%	10.5%	10.5%
WW	572	487	17.5%	9.3%	8.2%

ORAL CARE

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	185	186	-0.5%	-0.5%	-
Intl	223	168	32.7%	20.8%	11.9%
WW	408	354	15.3%	9.7%	5.6%

OTC/NUTRITIONALS

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	679	584	16.3%	16.3%	-
Intl	726	622	16.7%	5.1%	11.6%
WW	1,405	1,206	16.5%	10.5%	6.0%

WOMEN'S HEALTH

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	158	163	-3.1%	-3.1%	-
Intl	346	300	15.3%	3.3%	12.0%
WW	504	463	8.9%	1.1%	7.8%

WOUND CARE / OTHER

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	182	185	-1.6%	-1.6%	-
Intl	126	112	12.5%	0.6%	11.9%
WW	308	297	3.7%	-0.8%	4.5%

TOTAL CONSUMER

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	1,694	1,562	8.5%	8.5%	-
Intl	2,342	2,002	17.0%	5.6%	11.4%
WW	4,036	3,564	13.2%	6.8%	6.4%

	2008	2007	% Change		
			Reported	Operational (1)	Currency
US	761	695	9.5%	9.5%	-
Intl	918	826	11.1%	0.1%	11.0%
WW	1,679	1,521	10.4%	4.4%	6.0%
US	226	215	5.1%	5.1%	-
Intl	879	719	22.3%	11.7%	10.6%
WW	1,105	934	18.3%	10.1%	8.2%
US	384	389	-1.3%	-1.3%	-
Intl	410	324	26.5%	15.3%	11.2%
WW	794	713	11.4%	6.3%	5.1%
US	1,521	1,239	22.8%	22.8%	-
Intl	1,478	1,224	20.8%	8.4%	12.4%
WW	2,999	2,463	21.8%	15.7%	6.1%
US	306	326	-6.1%	-6.1%	-
Intl	659	558	18.1%	5.9%	12.2%
WW	965	884	9.2%	1.5%	7.7%
US	315	327	-3.7%	-3.7%	-
Intl	243	218	11.5%	-0.3%	11.8%
WW	558	545	2.4%	-2.3%	4.7%
US	3,513	3,191	10.1%	10.1%	-
Intl	4,587	3,869	18.6%	7.0%	11.6%
WW	8,100	7,060	14.7%	8.3%	6.4%

(1) Operational growth excludes the effect of currency

(2) Select areas (unaudited)